India's Cipla jumps on FDA approval for Ventolin HFA generic inhaler

GlaxoSmithKline Pharmaceuticals

23/04/2026 10:55

**Shares of Cipla CIPL.NS rise 5.6% to 1,305 rupees, set for third consecutive session of gains

** Drugmaker receives U.S. FDA approval for its Abbreviated New Drug Application for generic equivalent of inhaler Ventolin HFA, marketed by GlaxoSmithKline GLAX.NS

** Drug is indicated for the treatment or prevention of brochospasms in adults or children aged four and above

** More than 4.6 million shares change hands vs 30 day avg of 1.7 million shares

** Stock rated as "Hold" on average by 37 analysts; median PT at 1,438 rupees as per data compiled by LSEG

** YTD, stock down 13.7%

 (Reporting by Mridula Kumar in Bengaluru)

 ((Mridula.Kumar@thomsonreuters.com;))